A study of the combination of oxaliplatin, capecitabine, and herceptin (trastuzumab) and chemoradiotherapy in the adjuvant setting in operated patients with HER2+gastric or gastro-esophageal junction cancer (TOXAG study).
Atıf İçin Kopyala
Abali H. , Yalcin S. , Onal H. C. , Dane F., Oksuzoglu B., Ozdemir N., ...Daha Fazla
Gastrointestinal Cancers Symposium, San-Francisco, Kostarika, 21 - 23 Ocak 2016, cilt.34
